Protalix BioTherapeutics, Inc. (PLX) Fair Value 2026

PLX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.9 /10

32 fundamental signals · 3 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, Protalix BioTherapeutics, Inc. (PLX) trades at $2.61, versus a $1.16 median fair value across its 3 active models — 55.6% below the current price. QOC: 6.9/10. Value Trap Risk: 35/100 (LOW). 3/13 models active.

Key Facts

Ticker
PLX
Price
$2.61
Quality Score
6.9/10
Value Trap Risk
35/100
Models Active
3/13
Last Updated
Strength: 3 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Protalix BioTherapeutics, Inc. (PLX) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Protalix BioTherapeutics, Inc. (PLX) appears overvalued as of : the median of 3 independent fair value estimates is $1.16, 55.6% below the current price of $2.61. Estimates range from $0.24 to $1.71. PLX scores 6.9/10 on fundamental quality and 35/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. PLX’s -55.6% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Protalix BioTherapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give PLX?

3 Intrinsic Value Models vs. Current Price ($2.61)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $1.71 -34.6%
Relative · Medium Conviction
 $0.24 -90.7%
Relative · Low Conviction
 $1.16 -55.6%

All Models Active

All 3 models are displayed above.

What Is PLX's Fair Value Range?

Spread across 3 independent models · $0.24 to $1.71

CirclFi's 3 active models place Protalix BioTherapeutics, Inc. (PLX) between $0.24 and $1.71 per share, a spread of 126% of the median. The median of that range — $1.16 — is the fair value CirclFi publishes for PLX, against a current price of $2.61.

Low · Regime CrossHigh · ML-RIV
$0.24median $1.16$1.71
Where the range comes from
Most bearish modelRegime Cross-Sectional$0.24
Most bullish modelML Residual Income$1.71
Model agreement0 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for PLX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on PLX, not a CirclFi price target. How each model works →

What Is Protalix BioTherapeutics, Inc. (PLX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Protalix BioTherapeutics, Inc.'s intrinsic value is estimated at $1.16. Trading at its current price of $2.61, the valuation engine raises significant caution: 3 of 3 models flag downside risk, projecting a median implied return of -55.6%. Notably, ML-RIV sees the most upside at -34.6% (fair value: $1.71), while Regime Cross is the most conservative at -90.7% ($0.24). The spread between these extremes — +56.1% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About PLX?

3 of 13 models are currently active for PLX. All 3 active models suggest the stock trades above fair value. Taken together, their median fair value for PLX is $1.16 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does PLX Rank in Biotechnology?

Among 620 Biotechnology stocks, PLX ranks #56 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Protalix BioTherapeutics, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is PLX a Value Trap?

CirclFi's Value Trap algorithm assigns PLX a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Protalix BioTherapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Protalix BioTherapeutics, Inc. earns a quality score of 6.9/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +56.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PLX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PLX's 3 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Protalix BioTherapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

LCTXLineage Cell Therapeutics, Inc.QOC 6.9FDMT4D Molecular Therapeutics, Inc.QOC 6.8FHTXFoghorn Therapeutics Inc.QOC 6.9ICCCImmuCell CorporationQOC 6.8NRIXNurix Therapeutics, Inc.QOC 6.9OCGNOcugen, Inc.QOC 6.8ADXNAddex Therapeutics LtdQOC 5.5NAUTNautilus Biotechnology, Inc.QOC 4.8TENXTenax Therapeutics, Inc.QOC 4.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: LCTX · FDMT · FHTX · ICCC · NRIX · OCGN · ADXN · NAUT · TENX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PLX?

7 companies across all industries closest to PLX’s Quality of Company score of 6.9/10.

KMXCarMax, Inc.QOC 6.9CCICrown Castle Inc.QOC 6.9OBDCBlue Owl Capital CorporationQOC 6.9AOSLAlpha and Omega Semiconductor LimitedQOC 6.9SOFISoFi Technologies, Inc.QOC 6.9ESOAEnergy Services of America CorporationQOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: KMX · CCI · OBDC · AOSL · SOFI · ESOA · NVDA

Where Does PLX Sit in CirclFi's Biotechnology Rankings?

PLX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Protalix BioTherapeutics, Inc.’s Valuation?

What is Protalix BioTherapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Protalix BioTherapeutics, Inc. (PLX)'s intrinsic value at $1.16 — the median of 3 independent model estimates as of 2026-08-27, ranging from $0.24 to $1.71. The Quality of Company score is 6.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PLX overvalued or undervalued right now?

At $2.61, 0 of 3 active models suggest PLX may be undervalued, while 3 indicate potential overvaluation. The median of all 3 fair value estimates is $1.16, 55.6% below the current price of $2.61 — a consensus view that PLX is overvalued. The assessment depends on which methodology best fits Protalix BioTherapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.9 mean for PLX?

Protalix BioTherapeutics, Inc.'s QOC of 6.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PLX?

CirclFi analyzes PLX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on PLX?

Of the 3 models currently active on PLX, ML Residual Income is the most bullish at $1.71 per share, and Regime Cross-Sectional is the most bearish at $0.24. CirclFi's published fair value for PLX is the median of that range, $1.16, not either extreme. The gap between the two ends equals 126% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is PLX a value trap in 2026?

Protalix BioTherapeutics, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Protalix BioTherapeutics, Inc. (PLX) has a median fair value of $1.16 — 55.6% below the current price of $2.61 — as of 2026-08-27.” Source: circlfi.com/stock/PLX/ · Methodology
Primary sources for this PLX valuation
  • Financial statements: Protalix BioTherapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001006281) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PLX as of ; valuations recomputed .